Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 8.54
NAS:XENE's Cash-to-Debt is ranked lower than
61% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. NAS:XENE: 8.54 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:XENE' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.1  Med: No Debt Max: No Debt
Current: 8.54
5.1
No Debt
Debt-to-Equity 0.13
NAS:XENE's Debt-to-Equity is ranked higher than
55% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. NAS:XENE: 0.13 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:XENE' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.02  Med: 0.19 Max: 0.24
Current: 0.13
-0.02
0.24
Debt-to-EBITDA -0.44
NAS:XENE's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. NAS:XENE: -0.44 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:XENE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.49  Med: -0.35 Max: -0.21
Current: -0.44
-0.49
-0.21
Piotroski F-Score: 1
Altman Z-Score: 3.63
Beneish M-Score: 40.62
WACC vs ROIC
9.33%
6034.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -13440.36
NAS:XENE's Operating Margin % is ranked lower than
93% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. NAS:XENE: -13440.36 )
Ranked among companies with meaningful Operating Margin % only.
NAS:XENE' s Operating Margin % Range Over the Past 10 Years
Min: -13440.36  Med: -60.1 Max: 39.15
Current: -13440.36
-13440.36
39.15
Net Margin % -12144.29
NAS:XENE's Net Margin % is ranked lower than
92% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. NAS:XENE: -12144.29 )
Ranked among companies with meaningful Net Margin % only.
NAS:XENE' s Net Margin % Range Over the Past 10 Years
Min: -12144.29  Med: -101.12 Max: 45.89
Current: -12144.29
-12144.29
45.89
ROE % -57.60
NAS:XENE's ROE % is ranked lower than
60% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. NAS:XENE: -57.60 )
Ranked among companies with meaningful ROE % only.
NAS:XENE' s ROE % Range Over the Past 10 Years
Min: -61.51  Med: -36.81 Max: -23.54
Current: -57.6
-61.51
-23.54
ROA % -52.13
NAS:XENE's ROA % is ranked lower than
66% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NAS:XENE: -52.13 )
Ranked among companies with meaningful ROA % only.
NAS:XENE' s ROA % Range Over the Past 10 Years
Min: -54.05  Med: -17.2 Max: 20.43
Current: -52.13
-54.05
20.43
ROC (Joel Greenblatt) % -3241.95
NAS:XENE's ROC (Joel Greenblatt) % is ranked lower than
71% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. NAS:XENE: -3241.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:XENE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3241.95  Med: -371.38 Max: 539.88
Current: -3241.95
-3241.95
539.88
3-Year Revenue Growth Rate -86.70
NAS:XENE's 3-Year Revenue Growth Rate is ranked lower than
89% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:XENE: -86.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:XENE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -86.7  Med: -62.4 Max: 29.7
Current: -86.7
-86.7
29.7
GuruFocus has detected 5 Warning Signs with Xenon Pharmaceuticals Inc NAS:XENE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:XENE's 30-Y Financials

Financials (Next Earnings Date: 2019-03-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

XENE Guru Trades in Q4 2017

Jim Simons 249,000 sh (+59.21%)
Steven Cohen 310,179 sh (unchged)
Wilbur Ross 341,884 sh (-9.02%)
» More
Q1 2018

XENE Guru Trades in Q1 2018

Jim Simons 288,000 sh (+15.66%)
Wilbur Ross 341,884 sh (unchged)
Steven Cohen 307,079 sh (-1.00%)
» More
Q2 2018

XENE Guru Trades in Q2 2018

Jim Simons 489,500 sh (+69.97%)
Wilbur Ross 248,823 sh (-27.22%)
Steven Cohen 78,100 sh (-74.57%)
» More
Q3 2018

XENE Guru Trades in Q3 2018

Pioneer Investments 11,200 sh (New)
Louis Moore Bacon 15,000 sh (New)
Jim Simons 527,337 sh (+7.73%)
Steven Cohen 400,000 sh (+412.16%)
Wilbur Ross 129,539 sh (-47.94%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:XENE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:TSXV:MPH, ROCO:6469, SGX:42C, NAS:GLMD, XKLS:7178, XTER:WL6, TSE:4591, NGM:MERT MTF A, XPAR:ALONC, NAS:RGLS, TSE:4570, TSXV:TBP, TSE:4583, ASX:NOX, ROCO:6610, XKRX:106190, NAS:NOVN, TSE:4588, XKRX:000220, NAS:LIFE » details
Traded in other countries:XP0.Germany,
Headquarter Location:Canada
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.

Xenon Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of therapeutics for orphan indications. The company has developed a gene therapy referred as Glybera for the treatment of a subset of patients with the orphan lipid disorder lipoprotein lipase deficiency. The other product candidates include TV-45070, GDC-0310, XEN801 and XEN901 and other compounds in preclinical and discovery pipeline.

Ratios

vs
industry
vs
history
PB Ratio 1.33
XENE's PB Ratio is ranked lower than
70% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. XENE: 1.33 )
Ranked among companies with meaningful PB Ratio only.
XENE' s PB Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.09 Max: 16.58
Current: 1.33
0.96
16.58
EV-to-EBIT -1.85
XENE's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. XENE: -1.85 )
Ranked among companies with meaningful EV-to-EBIT only.
XENE' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.4  Med: -2.5 Max: 50.2
Current: -1.85
-11.4
50.2
EV-to-EBITDA -1.86
XENE's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. XENE: -1.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
XENE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.3  Med: -2.6 Max: 42
Current: -1.86
-13.3
42
EV-to-Revenue 230.12
XENE's EV-to-Revenue is ranked lower than
93% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. XENE: 230.12 )
Ranked among companies with meaningful EV-to-Revenue only.
XENE' s EV-to-Revenue Range Over the Past 10 Years
Min: -3.7  Med: 10.4 Max: 11815.7
Current: 230.12
-3.7
11815.7
Current Ratio 29.34
XENE's Current Ratio is ranked higher than
92% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. XENE: 29.34 )
Ranked among companies with meaningful Current Ratio only.
XENE' s Current Ratio Range Over the Past 10 Years
Min: 2.62  Med: 13.17 Max: 29.34
Current: 29.34
2.62
29.34
Quick Ratio 29.34
XENE's Quick Ratio is ranked higher than
92% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. XENE: 29.34 )
Ranked among companies with meaningful Quick Ratio only.
XENE' s Quick Ratio Range Over the Past 10 Years
Min: 2.62  Med: 13.17 Max: 29.34
Current: 29.34
2.62
29.34
Days Sales Outstanding 234.64
XENE's Days Sales Outstanding is ranked lower than
92% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. XENE: 234.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
XENE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.77  Med: 8.69 Max: 514.05
Current: 234.64
2.77
514.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.30
XENE's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. XENE: -8.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XENE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -104.1  Med: -89.25 Max: -8.3
Current: -8.3
-104.1
-8.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.25
XENE's Price-to-Net-Cash is ranked higher than
68% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. XENE: 1.25 )
Ranked among companies with meaningful Price-to-Net-Cash only.
XENE' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.18  Med: 2.15 Max: 4.04
Current: 1.25
1.18
4.04
Price-to-Net-Current-Asset-Value 1.37
XENE's Price-to-Net-Current-Asset-Value is ranked lower than
56% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. XENE: 1.37 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
XENE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.16  Med: 2.08 Max: 15.81
Current: 1.37
1.16
15.81
Price-to-Tangible-Book 1.36
XENE's Price-to-Tangible-Book is ranked lower than
63% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. XENE: 1.36 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
XENE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.12  Med: 2 Max: 13.21
Current: 1.36
1.12
13.21
Price-to-Median-PS-Value 131.40
XENE's Price-to-Median-PS-Value is ranked lower than
99% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. XENE: 131.40 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
XENE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.8 Max: 264
Current: 131.4
0.07
264
Earnings Yield (Greenblatt) % -54.02
XENE's Earnings Yield (Greenblatt) % is ranked lower than
63% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. XENE: -54.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
XENE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8117.4  Med: -28.3 Max: 5221.5
Current: -54.02
-8117.4
5221.5

More Statistics

Revenue (TTM) (Mil) $0.28
EPS (TTM) $ -1.74
Beta1.17
Volatility83.28%
52-Week Range $2.36 - 15.92
Shares Outstanding (Mil)25.24

Piotroski F-Score Details

Piotroski F-Score: 11
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}